Overview
Risankizumab is a newer biologic that selectively targets IL-23 (specifically its p19 subunit) without blocking IL-12, providing more targeted suppression of the Th17 inflammatory pathway. It is approved for moderate-to-severe Crohn's disease and ulcerative colitis.
Key Uses
Moderate-to-severe Crohn's disease
Moderate-to-severe ulcerative colitis
Patients who have failed or are intolerant to conventional therapy or biologics
Also approved for plaque psoriasis
How It Works
Selectively binds the p19 subunit of IL-23 — spares IL-12, preserving some protective immune functions
Reduces Th17 cell activity and downstream inflammation in the gut
Induction (Crohn's): IV infusions at weeks 0, 4, and 8; maintenance: 360 mg SC every 8 weeks
Induction (UC): 1200 mg IV at week 0; maintenance: 180 or 360 mg SC every 8 weeks
Safety & Self-Care
TB and hepatitis B screening required before starting
Generally well tolerated; injection site reactions and upper respiratory infections are most common
Avoid live vaccines during treatment
Keep all scheduled infusion and injection appointments
Report any unusual infections or skin changes promptly
Contact Your IMCC Team
Contact your IMCC team if symptoms worsen, you develop infection, or before any planned surgery or pregnancy.
Share this with someone who needs it: